855 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug http://www.zacks.com/stock/news/415333/immunogen-plunges-as-fda-recommends-new-study-for-lead-drug?cid=CS-ZC-FT-415333 May 16, 2019 - FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer http://www.zacks.com/stock/news/414385/pfizers-bavencio%2Binlyta-combo-gets-fda-nod-for-kidney-cancer?cid=CS-ZC-FT-414385 May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-ZC-FT-413860 May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
What's in Store for Affimed (AFMD) This Earnings Season? http://www.zacks.com/stock/news/413239/whats-in-store-for-affimed-afmd-this-earnings-season?cid=CS-ZC-FT-413239 May 13, 2019 - Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/412848/endo-endp-q1-earnings-revenues-beat-estimates?cid=CS-ZC-FT-412848 May 10, 2019 - Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/412101/intercept-icpt-q1-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-412101 May 09, 2019 - Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More http://www.zacks.com/stock/news/411198/drug-biotech-stock-q1-earnings-on-may-9-ions-xlrn-more?cid=CS-ZC-FT-411198 May 08, 2019 - Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates http://www.zacks.com/stock/news/411124/array-biopharma-arry-q3-earnings-and-sales-beat-estimates?cid=CS-ZC-FT-411124 May 08, 2019 - Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.

Pages: 123456789...86

<<<Page 4>